Neovasc — Investor Presentation (January 2012)
21 slides from Neovasc's investor presentation, Jan 17, 2012
Slide 1: Neovasc Inc.
Neovasc Inc. Alexei Marko, CEO January 2012
Slide 2: Forward-Looking Statements
Forward-Looking Statements Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words “anticipates,” “believes,” “may,” “continues,” “estimates,” “expects,” and “will” and words of similar import, constitute “forward-loo
Slide 3: Neovasc at-a-Glance
Neovasc at-a-Glance • Focused on innovative products to treat heart disease and related conditions • Three key product lines under development with large growth potential: 1. Neovasc Reducer™ for treatment of refractory angina (CE marked) 2. Implantable biological tissue and services for transcathet
Slide 4: Reducer Product
Reducer Product Treats Refractory Angina • Inadequate blood flow to heart muscle that cannot be managed through conventional drug, catheter or surgical therapy • Causes constant & severe heart pain • Large & growing population of untreatable patients – Improved cardiac care Æ less mortality & more p
Slide 5: Reducer Market Opportunity
Reducer Market Opportunity • ~ 2,000,000 existing “no option” refractory angina patients in US & Europe • ~400,000 new “no option” patients diagnosed annually • ~1,000,000 patients/year treated for “recurrent” angina 5
Slide 6: Reducer Method of Action
Reducer Method of Action Reducer modulates outflow of blood from coronary veins, increasing blood flow to ischemic areas Blood flow takes path of Venous back pressure least resistance causes more uniform distribution of blood • Majority of blood flows flow through heart around ischemic muscle areas
Slide 7: Reducer Procedure
Reducer Procedure • Based on 1950’s surgical procedure (Beck Procedure) • Reported excellent results but is no longer performed due to surgery’s invasiveness • Neovasc Reducer achieves same narrowing using modern non-surgical catheter-based techniques • Reducer procedure takes ~20 minutes; patient d
Slide 8: Reducer Clinical Results
Reducer Clinical Results Compelling clinical data from 1st human trial (15 patients, 3 centers) • 6-month data published in May 2007 JACC demonstrated safety & significant improvement of angina symptoms • 3-year follow-up data confirms excellent long-term safety & treatment durability (presented at
Slide 9: Reducer COSIRA Trial
Reducer COSIRA Trial COSIRA (Coronary Sinus Reducer for Treatment of Refractory Angina) Double-blind, randomized, sham-controlled, multicenter, prospective trial • 124 patients • Randomized 1:1 to blinded treatment & sham control arms • Primary endpoint: Efficacy @ 6-months • Sites in Belgium, Canad
Slide 10: Reducer Commercialization Timeline
Reducer Commercialization Timeline 1. Europe: • CE mark received November 2011 • Continue to focus on COSIRA trial enrollment • Collect additional clinical data through patient registries being initiated in Europe (REDUCE-1), Israel (REDUCE-2) and Canada (REDUCE-3) • Launch with distribution partner
Slide 11: Biological Tissue Products
Biological Tissue Products • Proprietary process creates implantable, biocompatible tissue that retains strength & physical characteristics of natural tissue • Developed specifically for fabricating surgical heart valves • 20+ year implant history • FDA-cleared, CE-marked, EDQM certified • State-of-
Slide 12: Biological Tissue Business
Biological Tissue Business Neovasc provides: • Custom biological tissue to a wide range of industry partners for use in their devices such as surgical patches and transcatheter heart valves • Development & prototyping services for devices incorporating pericardial tissue • Pilot & commercial manufac
Slide 13: Rapid Growth in Heart Valve Applications
Rapid Growth in Heart Valve Applications • 2011 worldwide sales of ~$600M and 2012 sales forecast to be ~$900M from 1st generation transcatheter aortic valves • Significant growth in market expected as 2nd & 3rd generation products reach commercialization Neovasc is the leading independent supplier
Slide 14: Tiara Mitral Valve Replacement
Tiara™ Mitral Valve Replacement Neovasc is developing Tiara™-- a novel transcatheter device for the treatment of mitral regurgitation (MR). MR is a serious and widespread condition that can cause significant disability or death. Tiara is delivered using a catheter inserted through the apex of the he
Slide 15: Tiara Key Features
Tiara Key Features 1. Design is specific to the mitral anatomy & matches the natural shape of the mitral annulus 2. Resists high dislodgment forces during systole 3. Exerts minimal radial force on the mitral annulus 4. Does not inhibit LV function or obstruct LVOT 5. Preserves native structures in t
Slide 16: Tiara Development Progress
Tiara Development Progress • Multiple patent applications filed • Refined valves and transapical delivery systems developed • Preclinical testing underway (bench, acute / chronic animal) • Durability (accelerated wear) testing in progress • Clinical technique developed and refined through multiple a
Slide 17: Tiara Market Opportunity
Tiara Market Opportunity • Success of transcatheter aortic valves has positioned transcatheter mitral valve replacement as a major area of industry/clinical interest • 600,000 new patients per year with mitral regurgitation in US and EU • Only 20% of diagnosed patients currently undergo surgery • Mi
Slide 18: Clinical Opinion Leaders
Clinical Opinion Leaders Leaders in interventional cardiology are assisting Neovasc programs • Dr. Shmuel Banai (Tel Aviv Medical Center) • Dr. Elazer Edelman (Harvard – MIT, Cambridge) • Dr. Tim Henry (Minneapolis Heart Institute) • Dr. Marc Jolicoeur (Montreal Heart Institute) • Dr. Martin Leon (C
Slide 19: 2012: Looking Forward
2012: Looking Forward Continued growth of tissue business (2011 ~$5.25M) • Expect steady growth in 2012 with upside potential as customers’ new products are commercialized Complete COSIRA trial for Reducer and launch in Europe • Controlled EU release in near-term to build clinical experience / data
Slide 20: Capitalization & Trading
Capitalization & Trading • 45.7m (issued and outstanding) Shares outstanding • 54.5m (fully diluted) Public listing • TSXV: NVC • Frost Group • Gagnon Securities Key investors • OPKO Health • Company directors and management • August 2011 financing oversubscribed (raised $4.7M) Cash requirements • C
Slide 21: Thank you
Thank you 21